One particular healthcare stock has shown its ability to soar on good news -- and it's had plenty of it. This year the ...

The jump in prescription fills comes despite limited insurance coverage and high out-of-pocket costs for Novo Nordisk's Wegovy and Eli Lilly's Zepbound.

Randomised controlled trials and real word evidence have consistently shown that GLP-1 receptor agonists are effective and ...

Matt Christensen kicked heroin by replacing drugs with drinking. When he stopped drinking in 2022, he turned to food. He put ...

The darlings of the weight loss and diabetes spaces, GLP-1 receptor agonists have shown promise against Alzheimer’s in recent studies—with Phase III results expected next year from Novo Nordisk.

With so many weight loss medications on the market, it's easy to feel overwhelmed by the options. From brand-name heavy ...

It offers more evidence of the insatiable demand for a buzzy class of medications called GLP-1 and GIP agonists, which have hefty list prices of roughly $1,000 per month before insurance or ...